文献速递临床微生物质量管理与危急值

VITEK REVEAL与Accelerate Pheno在革兰阴性菌血流感染快速药敏检测中的性能比较

Comparison of the VITEK REVEAL AST and Accelerate Pheno systems for fast antimicrobial susceptibility testing of gram-negative blood cultures at a large academic health system.
PubMed 文献 · J Clin Microbiol · 2025-12-17

本研究在大规模学术医疗系统中比较了VITEK REVEAL与Accelerate Pheno两种快速药敏检测系统直接用于革兰阴性菌阳性血培养的性能,分析了128例样本。结果显示两系统分类一致率为94.3%,基本一致率为96.0%,VITEK REVEAL可实时报告MIC结果,有助于抗菌药物管理。

要点

  • VITEK REVEAL与Accelerate Pheno药敏检测分类一致率达94.3%,基本一致率达96.0%。
  • VITEK REVEAL可实时报告MIC结果,较Accelerate Pheno更早提供可操作信息。
  • VITEK REVEAL对耐药菌株的序贯报告时间显著短于敏感/中介菌株,平均差1.4小时。

核心结论

  • VITEK REVEAL直接用于革兰阴性菌阳性血培养药敏检测,与Accelerate Pheno相比具有高分类一致率和基本一致率。
  • VITEK REVEAL可实时报告MIC结果,有利于抗菌药物管理和早期释放可操作信息。

研究设计与样本

  • 研究分析了128例革兰阴性菌阳性血培养,按照制造商推荐方法进行检测。
  • 比较了VITEK REVEAL与Accelerate Pheno(作为标准护理方法)的报告时间及药敏结果。

主要发现

  • VITEK REVEAL与Accelerate Pheno的分类一致率为94.3%,基本一致率为96.0%。
  • 极重大不一致率、重大不一致率和次要不一致率分别为7.5%、0.5%和4.1%。
  • VITEK REVEAL的平均序贯报告时间为6.1小时(范围3.0-8.2小时),平均最终报告时间为7.9小时(范围6.5-8.2小时)。
  • Accelerate Pheno的平均最终报告时间为7.1小时(范围6.8-7.7小时),显著短于VITEK REVEAL。
  • VITEK REVEAL对耐药菌株的序贯报告时间显著短于敏感/中介菌株,平均差1.4小时(P < 0.001)。

临床怎么用

  • VITEK REVEAL可用于革兰阴性菌阳性血培养的直接快速药敏检测,实时报告MIC结果。
  • 两系统一致性高,但VITEK REVEAL在耐药菌株中报告时间更短,可能更有利于早期调整抗菌治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Timely initiation of appropriate antimicrobial therapy is crucial for patients with Gram-negative (GN) blood stream infections. In this study, the performance of VITEK REVEAL (bioMérieux, USA), an FDA cleared in vitro diagnostic automated system for antimicrobial susceptibility testing (AST) directly from positive blood culture (BC), was compared to that of Accelerate Pheno (Accelerate Diagnostics, USA), as standard of care method. 128 GN positive BCs were analyzed according to manufacturer recommendations, comparing time to result (TTR) and AST results. The categorical agreement (CA) rate between VITEK REVEAL and Accelerate Pheno was 94.3% and the essential agreement (EA) rate was 96.0%. Very major discrepancies (VMD), major discrepancies (MD), and minor discrepancies (miD) rates between the systems were 7.5%, 0.5%, and 4.1%, respectively. Lastly, we observed a mean sequential TTR (reporting of AST results per antibiotic in real-time) on VITEK REVEAL of 6.1 h (3.0-8.2) and mean final TTR of 7.9 h (6.5-8.2), compared to Accelerate Pheno, with a significantly shorter mean final TTR of 7.1 h (6.8-7.7). Sequential TTR on VITEK REVEAL was significantly shorter for resistant isolates (those with ≥1 'Resistant' antimicrobial-organism combination interpretation, using FDA STIC 2024 or CLSI M100 criteria) compared to susceptible/intermediate ones, with a mean difference of 1.4 h (P < 0.001). Overall, compared to Accelerate Pheno, VITEK REVEAL displayed high %CA and %EA for AST of GN bacteria directly from positive BC. Also, unlike Accelerate Pheno, VITEK REVEAL reports MIC results in real time, allowing an earlier release of actionable information useful for antimicrobial stewardship. IMPORTANCE: Previous studies have compared the performance of the VITEK REVEAL, system for fast antimicrobial susceptibility testing (AST) to conventional, non-rapid microbiology methods. To evaluate how the VITEK REVEAL correlates to similarly available fast, direct-from-blood culture AST technologies, this study aimed to compare it to the Accelerate Pheno system, as standard of care method. High categorical agreement (94.3%) and essential agreement (96.0%) between the two systems were observed, underscoring their reliability. The VITEK REVEAL has the advantage of real-time AST reporting, unlike the Accelerate Pheno. Ultimately, this study supports the need for and continued optimization of fast diagnostic technologies for AST, contributing to the goal of advancing antimicrobial stewardship-focused treatment strategies and improving the prognosis of patients with bloodstream infections.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Simmons-Williams C, Soares L, Becker D, et al. Comparison of the VITEK REVEAL AST and Accelerate Pheno systems for fast antimicrobial susceptibility testing of gram-negative blood cultures at a large academic health system. J Clin Microbiol. 2025. PMID: 41406025. doi:10.1128/jcm.01073-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。